Investor Income

Business

Aon Caps Off Strategic Three-Year Plan with Strong 2025, Eyes Data Center Boom and $7B War Chest for Growth

The global professional services firm reported 6% organic revenue growth for the second consecutive year, fueled by its Aon United strategy and strategic acquisitions like NFP. With $7 billion in available capital, Aon is poised to accelerate investments in high-growth areas, notably the burgeoning data center and alternative capital markets.

Jan 30, 2026

Business

Charter Navigates Competitive Headwinds, Bets on Convergence and Service Guarantees to Drive 2026 Growth

Charter Communications reported mixed Q4 2025 results, with continued broadband subscriber pressure offset by strong mobile growth and improved video trends. CEO Chris Winfrey outlined a strategy centered on 'guaranteed' connectivity, savings, and leveraging its converged network to win in a fiercely competitive market, while CFO Jessica Fischer signaled a shift towards a more conservative balance sheet.

Jan 30, 2026

Business

BofA Lifts Greif Price Target to $75, Maintains Neutral Stance Amid Packaging Sector Review

Bank of America has increased its price target for industrial packaging firm Greif (GEF) by $1 to $75, while reiterating a Neutral rating. The adjustment follows the bank's broader reassessment of the packaging sector after recent quarterly earnings calls.

Jan 30, 2026

Business

Truist Stands By DLocal With Price Target Hike, Eyes Strong Q4 Amid Tough Comparisons

Analysts at Truist reaffirm their Buy rating on DLocal (DLO), raising their price target to $17 ahead of the fintech firm's Q4 2025 earnings. While expecting solid results, they flag challenging year-over-year volume comparisons that may cap upside surprises.

Jan 30, 2026

Business

Goldman Sachs Lifts Zeta Global Target to $26, Eyes Software M&A Wave on Horizon

Goldman Sachs raises its price target for Zeta Global (ZETA), citing strategic positioning ahead of an expected surge in software sector mergers and acquisitions driven by valuation gaps and synergy potential.

Jan 30, 2026

Business

Analysts Eye Credo Technology's AI Data Center Role, But Competition Looms

Rosenblatt Securities initiates coverage on Credo Technology with a Neutral rating and a $170 price target, highlighting its strong position in high-speed connectivity for AI infrastructure while flagging competitive pressures. The note follows a more bullish target hike from Barclays earlier in the month.

Jan 30, 2026

Business

Guggenheim More Than Doubles Erasca Price Target to $12 on Clinical Progress and Pipeline Updates

Erasca Inc. (ERAS) sees its price target raised from $5 to $12 by Guggenheim, following promising clinical data for its lead oncology candidates and updated financial models. The move comes amid a series of positive analyst revisions for the clinical-stage biopharma firm.

Jan 30, 2026

Business

Alumis Soars as Psoriasis Drug Hits All Phase 3 Goals, Drawing Bullish Analyst Praise

Clinical-stage biopharma Alumis Inc. (ALMS) is gaining significant Wall Street attention after its lead drug candidate, envudeucitinib, successfully met all endpoints in key Phase 3 trials for plaque psoriasis, prompting multiple analyst upgrades and optimistic price targets.

Jan 30, 2026

Business

Analyst Bullish on BrightSpire Capital, Citing Strong Liquidity to Fuel 2026 Growth

B.Riley initiates coverage on BrightSpire Capital (BRSP) with a Buy rating, highlighting its robust cash position and improved credit quality as key drivers for future loan originations, while its stock trades at a discount to book value.

Jan 30, 2026

Business

Piper Sandler Stays Bullish on AGNC Investment, Sees Opportunity in Narrowing MBS Spreads

Analyst firm Piper Sandler reiterates its Overweight rating on AGNC Investment Corp., highlighting a favorable shift in agency mortgage-backed securities spreads that could bolster the REIT's book value.

Jan 30, 2026

Business

UBS Backs Rithm Capital with Buy Rating, Sees Strategic Growth in $16 Billion Acquisition Spree

UBS initiates coverage on Rithm Capital with a Buy rating and a $16 price target, highlighting the REIT's aggressive acquisition strategy—including the purchases of Paramount Group and Crestline—as a key driver for expanding its asset management footprint and unlocking shareholder value.

Jan 30, 2026

Business

Wall Street Bets on SharpLink Gaming: Analysts See Upside Despite Crypto Volatility

SharpLink Gaming (NASDAQ: SBET) is drawing bullish attention from major Wall Street firms, with multiple analysts reiterating Buy ratings. The company's substantial Ethereum holdings and management's crypto expertise are seen as key drivers, even as price targets adjust to market conditions.

Jan 30, 2026

Business

Innodata Secures Key U.S. Missile Defense Agency Contract, Bolstering AI and Data Services Portfolio

Innodata Inc. (NASDAQ: INOD), a data engineering and AI services firm, has been awarded a place on a critical U.S. Missile Defense Agency contract vehicle, positioning it for future task orders in defense technology development and fueling analyst optimism for its 2026 growth trajectory.

Jan 30, 2026

Business

LifeSci Capital Boosts Price Target on Olema Pharmaceuticals, Citing Promising Breast Cancer Drug Pipeline

LifeSci Capital reaffirms its Buy rating on Olema Pharmaceuticals (OLMA) and raises its price target to $45, following bullish analyst sentiment on the company's lead drug candidate, Palazestrant, for ER+/HER2- breast cancer.

Jan 30, 2026

Business

Progress Software Surges on Strong Earnings, Analyst Upgrades

Progress Software Corporation (PRGS) sees bullish sentiment from Wall Street following its Q4 2025 results, with analysts highlighting its growing recurring revenue and strategic positioning in the enterprise software market.

Jan 30, 2026

Business

Immunocore Gains Analyst Backing as Late-Stage Trials Loom

Immunocore Holdings (NASDAQ: IMCR) has drawn renewed bullish sentiment from analysts at H.C. Wainwright and UBS, who highlight the stock's potential as key Phase 3 trial data for its cancer immunotherapies approaches later this decade.

Jan 30, 2026

Business

Truist Trims Tesla Target to $438, Maintains Hold as AI Pivot Weighs on Margins

Truist Securities has slightly lowered its price target on Tesla shares to $438, citing the significant capital expenditure required for the automaker's aggressive shift towards AI and robotics, despite a solid Q4 performance.

Jan 30, 2026

Business

Tesla Gets a Boost: TD Cowen Raises Price Target to $519, Citing Mixed Q4 Signals

Investment firm TD Cowen has increased its price target on Tesla (TSLA) to $519, maintaining a Buy rating. The adjustment follows a fourth-quarter performance marked by strong margins and progress on autonomous driving projects, though tempered by higher capital expenditure forecasts and vague timelines for full self-driving technology.

Jan 30, 2026

Business

Truist Trims Landstar System Price Target to $145 Amid Earnings Disappointment

Truist Securities has lowered its price target on Landstar System (LSTR) from $150 to $145, maintaining a Hold rating following the logistics provider's fourth-quarter earnings miss. Analysts cite one-time insurance costs as a drag, while noting core fundamentals have yet to show a decisive turnaround.

Jan 30, 2026

Business

Truist Lifts Meta Price Target to $900, Citing AI-Driven Ad Strength and Upbeat Guidance

Truist Securities raises its price target on Meta Platforms to $900, maintaining a Buy rating. The upgrade follows stronger-than-expected Q4 results and a robust Q1 outlook, driven by AI enhancements boosting ad performance and user engagement.

Jan 30, 2026